Citigroup upgraded shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) to a strong-buy rating in a report published on Friday, Zacks.com reports.
Separately, HC Wainwright reissued a buy rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a research note on Wednesday, May 15th.
View Our Latest Stock Analysis on Acumen Pharmaceuticals
Acumen Pharmaceuticals Stock Performance
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) last announced its quarterly earnings results on Monday, May 20th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). During the same quarter last year, the business posted ($0.28) EPS. As a group, sell-side analysts forecast that Acumen Pharmaceuticals will post -1.13 earnings per share for the current year.
Institutional Investors Weigh In On Acumen Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Gladius Capital Management LP acquired a new position in Acumen Pharmaceuticals in the second quarter valued at about $26,000. SG Americas Securities LLC acquired a new position in Acumen Pharmaceuticals in the first quarter valued at about $52,000. Chicago Partners Investment Group LLC grew its position in Acumen Pharmaceuticals by 34.9% in the fourth quarter. Chicago Partners Investment Group LLC now owns 18,315 shares of the company’s stock valued at $70,000 after acquiring an additional 4,736 shares during the last quarter. Citigroup Inc. grew its position in Acumen Pharmaceuticals by 5,423.4% in the third quarter. Citigroup Inc. now owns 38,498 shares of the company’s stock valued at $160,000 after acquiring an additional 37,801 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in Acumen Pharmaceuticals in the first quarter valued at about $253,000. Institutional investors and hedge funds own 71.01% of the company’s stock.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Further Reading
- Five stocks we like better than Acumen Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Is Crypto Cool Again? What Stocks You Should Be Watching
- 10 Best Airline Stocks to Buy
- Why Call Options Volume for These 2 Stocks Spiked Together
- 5 discounted opportunities for dividend growth investors
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.